ResMed Foundation
17
3
3
9
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
17.6%
3 terminated/withdrawn out of 17 trials
75.0%
-11.5% vs industry average
24%
4 trials in Phase 3/4
56%
5 of 9 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
Continuous Positive Airway Pressure, Arousability and Links to Mechanisms in Obstructive Sleep Apnea
Role: collaborator
Obstructive Sleep Apnea Treatment From Acute to Chronic Phase of Stroke
Role: collaborator
OSA-18 in Children With Mild Obstructive Sleep Apnea: Can it be a Helpful Decision Making Tool?
Role: collaborator
Auto-PAP Therapy For Improved Fetal Growth
Role: collaborator
Sleep Apnea and Fetal Growth Restriction
Role: collaborator
ASV for Sleep Apnea After Myocardial Infarction
Role: collaborator
Adaptive Servo-Ventilation In Acute Heart Failure Patients Protecting the Heart and Kidneys
Role: collaborator
PRevalence, Persistence and prOgnostic ValuE of Sleep Apnea Syndrome in Acute Heart Failure
Role: collaborator
Continuous Positive Airway Pressure (CPAP) Treatment in Coronary Artery Disease and Sleep Apnea
Role: collaborator
Cardiovascular Improvements With MV ASV Therapy in Heart Failure
Role: collaborator
The Sleep, Liver Evaluation and Effective Pressure Study
Role: collaborator
Home Mechanical Ventilation vs Home Oxygen Therapy in COPD
Role: collaborator
Sleep Apnea Treatment During Cardiac Rehabilitation of Congestive Heart Failure Patients
Role: collaborator
Atrial Fibrillation Recurrence in Sleep Apnea
Role: collaborator
Treatment Study of Soft Palatal Implants in Obstructive Sleep Apnea
Role: collaborator
Autoset T Versus CPAP Therapy, a Comparison of Titration and Therapy
Role: collaborator
Diagnosis and Treatment of Sleep-Disordered Breathing in the Homes of Patients With Transient Ischemic Attack
Role: collaborator
All 17 trials loaded